Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Breast symbols : Nvsef save search
Breast Cancer Therapeutics Market 2023, USD 15.64 billion Growth is Expected between 2023 to 2028, Robust pipeline and new drug approvals to Boost Growth - Technavio
Published: 2024-01-30 (Crawled : 18:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 5.68%
H: 0.77%
C: 0.77%
AZNCF | $135.94 -4.19% 770
|
Health Technology
|
| O: 3.41%
H: 0.0%
C: -2.45%
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
|
| O: -0.08%
H: 3.47%
C: -0.25%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: -2.04%
H: 0.19%
C: -1.97%
GSK | $39.95 -1.36% 0.0% 2.4M
|
Health Technology
|
| O: 4.04%
H: 1.57%
C: -3.02%
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: 0.5%
H: 0.07%
C: -0.81%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: 0.0%
PBYI | $5.1 -4.67% -4.9% 290K
|
Health Technology
|
| O: -0.1%
H: 2.31%
C: -1.26%
AZN | $68.27 -0.67% -0.67% 3.8M
|
Health Technology
|
| O: 0.82%
H: 0.12%
C: -1.64%
AMGN | $265.64 0.05% 0.05% 2M
|
Health Technology
|
| O: 0.44%
H: 0.2%
C: -0.55%
drug breast expected cancer pipeline therapeutics growth market
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions - December 8, 2023
Published: 2023-12-08 (Crawled : 16:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.29%
H: 0.4%
C: 0.4%
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.07%
H: 1.1%
C: 0.45%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 0.19%
H: 0.35%
C: 0.2%
kisqali breast risk novartis
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
Published: 2023-12-08 (Crawled : 14:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.29%
H: 0.4%
C: 0.4%
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.07%
H: 1.1%
C: 0.45%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 0.19%
H: 0.35%
C: 0.2%
kisqali breast risk novartis
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Published: 2023-10-20 (Crawled : 10:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: -0.42%
H: 0.16%
C: -1.32%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 0.6%
H: 0.61%
C: -0.56%
kisqali breast cancer risk novartis
Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Published: 2023-10-05 (Crawled : 06:00) - globenewswire.com
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: -1.21%
H: 1.3%
C: 1.16%
breast innovation cancer novartis
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
Published: 2023-09-18 (Crawled : 06:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: -1.31%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 0.06%
H: 0.09%
C: -0.6%
biosimilar chmp breast positive cancer
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
Published: 2023-06-02 (Crawled : 12:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.6%
H: 1.07%
C: 0.29%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 1.03%
H: 0.84%
C: 0.82%
kisqali breast risk novartis
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Published: 2023-04-26 (Crawled : 15:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: -2.04%
breast asco cancer kisqali novartis trial
Breast cancer therapeutics market size grow by USD 13.85 billion between 2021 to 2026; AbbVie Inc. and Amgen Inc., among others, emerge as key vendors - Technavio
Published: 2023-04-13 (Crawled : 09:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
AZNCF | $135.94 -4.19% 770
|
Health Technology
|
| O: 0.0%
H: 1.63%
C: 1.63%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.25%
H: 0.51%
C: 0.51%
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
|
| O: 0.31%
H: 1.42%
C: 0.71%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 1.3%
H: 0.56%
C: 0.51%
GSK | $39.95 -1.36% 0.0% 2.4M
|
Health Technology
|
| O: 0.85%
H: 0.76%
C: 0.76%
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: -0.84%
H: 1.16%
C: 1.05%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
PBYI | $5.1 -4.67% -4.9% 290K
|
Health Technology
|
| O: -0.34%
H: 10.17%
C: 6.9%
AZN | $68.27 -0.67% -0.67% 3.8M
|
Health Technology
|
| O: 0.39%
H: 1.05%
C: 0.97%
AMGN | $265.64 0.05% 0.05% 2M
|
Health Technology
|
| O: -0.36%
H: 1.33%
C: 1.14%
abbvie breast cancer therapeutics market
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
Published: 2023-03-27 (Crawled : 06:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.37%
H: 0.2%
C: -0.79%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 6.51%
H: 1.75%
C: 1.4%
kisqali breast cancer novartis trial
Breast Cancer Therapeutics Market Research Report 2023: Therapy, Chemotherapy Drugs, Hormone Therapy, Targeted Therapy - Global Forecasts to 2027
Published: 2023-03-04 (Crawled : 04:20) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
AZN | $68.27 -0.67% -0.67% 3.8M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.26 -0.52% 0.04% 12M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | $135.94 -4.19% 770
|
Health Technology
| Email alert
Add to watchlist
research global report breast therapeutics therapy cancer market hormone
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
Published: 2022-12-06 (Crawled : 19:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.85%
H: 0.0%
C: 0.0%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 1.04%
H: 0.37%
C: 0.05%
kisqali breast novartis cancer her2- her2 metastatic breast cancer
Breast Cancer Therapeutics Market Size to Grow by USD 13.85 Bn, Targeted Therapy to be Largest Revenue-generating Product Segment - Technavio
Published: 2022-10-27 (Crawled : 07:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: 0.0%
AZNCF | $135.94 -4.19% 770
|
Health Technology
|
| O: 1.47%
H: 0.21%
C: -0.7%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
|
| O: 0.1%
H: 0.85%
C: -1.1%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 0.06%
H: 0.44%
C: -0.15%
GSK | $39.95 -1.36% 0.0% 2.4M
|
Health Technology
|
| O: -0.12%
H: 0.47%
C: 0.21%
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: 0.82%
H: 0.15%
C: -0.17%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
PBYI | $5.1 -4.67% -4.9% 290K
|
Health Technology
|
| O: 1.32%
H: 0.43%
C: -3.46%
AZN | $68.27 -0.67% -0.67% 3.8M
|
Health Technology
|
| O: -0.48%
H: 0.56%
C: -0.12%
AMGN | $265.64 0.05% 0.05% 2M
|
Health Technology
|
| O: 0.5%
H: 0.49%
C: -0.29%
breast therapeutics therapy cancer market
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.